A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo in Subjects with Extensive-Disease Stage Small-Cell Lung Cancer (SCLC) after Completion of Platinum based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)
The purpose of this study is to show that maintenance therapy with nivolumab, or nivolumab plus ipilimumab followed by nivolumab alone, will prolong Overall Survival and Progression Free Survival compared with placebo in subjects with extensive stage disease small cell lung cancer who have completed first line chemotherapy.
• Subjects with histologically or cytologically confirmed extensive stage disease SCLC
• Ongoing response of stable disease or better following 4 cycles of platinum-based first line chemotherapy
Rachel Sanborn, M.D.
Bristol Myers Squibb (BMS)
- Oncology and Hematology Care Eastside
- Oncology and Hematology Care Westside